ContractProduction and Supply Agreement • December 5th, 2016 • Gw Pharmaceuticals PLC • Pharmaceutical preparations • England and Wales
***Certain portions of this exhibit have been omitted based on a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The omitted portions have been filed separately with the Securities and Exchange Commission.
MUTUAL TERMINATION AGREEMENTMutual Termination Agreement • December 5th, 2016 • Gw Pharmaceuticals PLC • Pharmaceutical preparations
This Mutual Termination Agreement (together with all Exhibits hereto, this “Termination Agreement”) is entered into as of 24 November 2016 (the “Termination Effective Date”) by and between Novartis Pharma AG, a company incorporated under the laws of Switzerland, with a place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland (hereinafter referred to as “Novartis”), and GW Pharma Ltd, a company incorporated under the laws of England and Wales (Company No. 03704998), having its registered address at Sovereign House, Vision Park, Chivers Way, Histon, Cambridge CB24 9BZ, UK (hereinafter referred to as “GW”). Novartis and GW, may hereinafter be referred to individually as a “Party” and collectively as the “Parties”.
